Page 4 - Sanofi India

Sanofi to reward shareholders with Rs 261 cr made from Ankleshwar unit sale

The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and brands

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Strong product mix, new launches to keep Sanofi India margins elevated

Street positive given attractive valuations; stock trading at 16x its CY20 estimates

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

Sanofi is already one of Ablynx's big pharma partners, after striking a deal in July 2017 to find new treatments for inflammatory diseases

Sanofi India Q2 net dips 14% at Rs 73 crore

The drug firm had posted a net profit of Rs 86.1 cr in the corresponding period of FY17

Stakeholders' body raises concerns over wilful defaulter on Sanofi's board

Proxy firm Stakeholders' Empowerment Services (SES) has raised concerns over the board composition of Sanofi India, where two former Kingfisher Airlines directors AK Ravi Nedungadi and Subash Gupte are serving as independent directors along with former RBI deputy governor Usha Thorat. "SES reiterates that there is no legal violation as far as board members are concerned. However, shareholders would be interested to know boardroom chemistry between an ex Regulator (Dr. Usha Thorat) and an ex-director of a company declared wilful defaulter," the firm said in a note ahead of the pharma major's annual general meeting on Friday. Kingfisher Airlines (KFA) has been declared as a willful defaulter by several banks after being grounded in October 2012 and its promoter Vijay Mallya is facing several proceedings including one to extradite him from UK. Nedungadi, who was a director of KFA till April 2014, had been associated with various Mallya businesses since the 1990s. Gupte, a former Air ...

Don't bring a drug under price control because it's widely sold: Shailesh Ayyangar

Interview with Managing Director, Sanofi India

Drug watchdog again finds Combiflam substandard

Yet again drug regulator finds painkiller 'sub-standard'

Drug pricing regime needs to be predictable, transparent: Sanofi

Stating the company understands its responsibility of making and distributing affordable essential medicines to all sections of society